JW Bioscience signs deal to supply BIOELAB's automated biochemical analyzers in Korea

JW Bioscience said Thursday that it has signed an exclusive supply agreement with China’s E-LAB Biological Science & Technology (BIOELAB) specializing in diagnostic analysis equipment to supply fully automated biochemical analysis equipment to Korean clients.

Under the agreement, JW Bioscience will exclusively supply BIOELAB's fully automated biochemical analysis equipment in Korea and expand sales of diagnostic reagents developed through its R&D technology.

The two fully automated biochemical analysis devices that JW Bioscience will introduce are AS-280 and AS-480, which chemically analyze various components contained in human blood to diagnose precisely the presence or absence of diseases in patients.

The lower model, AS-280, can analyze 40 samples and 80 diagnostic reagents at a time, while the higher model, AS-480, can analyze 120 samples and 90 diagnostic reagents.

With the introduction of fully automated biochemical analysis equipment, JW Bioscience plans to expand its share in the domestic diagnostic reagent market dominated by foreign products by strengthening sales of biochemical diagnostic reagents developed independently.

“With the introduction of biochemical analysis equipment recognized for its technology in the global market, we plan to focus on expanding sales of diagnostic reagents developed in-house,” a JW Bioscience official said, “We will continue to work closely together to expand our presence in the domestic biochemical analysis and diagnostic market.”

BIOELAB is a manufacturer specializing in biochemical analysis equipment and diagnostic reagents, holding the third largest market share of biochemical analysis equipment in China. It has sold more than 50,000 units of biochemical analyzers to the global market.